Armatus Bio
Armatus Bio is pioneering vectorized RNAi therapeutics for genetic neurological and neuromuscular diseases. They focus on precisely targeting disease-driving genes in autosomal dominant neuromuscular disorders, leveraging advanced RNA technology to develop life-changing medicines for conditions with no current therapeutic options. Their mission is to transform outcomes through precision RNAi, addressing significant unmet needs in neuromuscular diseases such as CMT1A and FSHD.
Industries
Nr. of Employees
small (1-50)
Armatus Bio
1275 Kinnear Road, Columbus, OH 43212
Products
AAV-delivered engineered microRNA therapeutic for peripheral nerve disease
Late preclinical program employing an AAV serotype-based vector expressing engineered microRNA to reduce overexpression of a disease-driving gene implicated in peripheral nerve demyelination, developed for one-time intrathecal administration.
Systemic AAV-delivered engineered microRNA therapeutic for muscle disease
Late preclinical program using systemically administered AAV with a myotropic capsid to deliver engineered microRNA that reduces toxic gene expression associated with a muscular dystrophy phenotype.
miRNA payload screening and translational fidelity platform (SPRINT)
Discovery platform for rapid evaluation and prioritization of microRNA payloads with emphasis on translational fidelity to accelerate selection of candidates for preclinical development.
AAV-delivered engineered microRNA therapeutic for peripheral nerve disease
Late preclinical program employing an AAV serotype-based vector expressing engineered microRNA to reduce overexpression of a disease-driving gene implicated in peripheral nerve demyelination, developed for one-time intrathecal administration.
Systemic AAV-delivered engineered microRNA therapeutic for muscle disease
Late preclinical program using systemically administered AAV with a myotropic capsid to deliver engineered microRNA that reduces toxic gene expression associated with a muscular dystrophy phenotype.
miRNA payload screening and translational fidelity platform (SPRINT)
Discovery platform for rapid evaluation and prioritization of microRNA payloads with emphasis on translational fidelity to accelerate selection of candidates for preclinical development.
Expertise Areas
- Vectorized RNAi therapeutics
- MicroRNA engineering and payload selection
- AAV vector and capsid engineering
- Preclinical development and IND-enabling studies
Key Technologies
- AAV-based vector delivery
- MicroRNA-based gene silencing
- miRNA payload screening platform
- Capsid engineering for tissue tropism